Skip to main content
Shanghai Hile Bio-Technology Co.,Ltd logo

Shanghai Hile Bio-Technology Co.,Ltd — Investor Relations & Filings

Ticker · 603718 ISIN · CNE1000022T4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,480 across all filing types
Latest filing 2025-10-28 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 603718

About Shanghai Hile Bio-Technology Co.,Ltd

http://www.hile-bio.com/

Shanghai Hile Bio-Technology Co., Ltd. specializes in the research, development, production, and distribution of veterinary biological products. The company focuses on providing comprehensive health solutions for the livestock and poultry sectors. Its core product portfolio includes a wide range of vaccines targeting major animal diseases, such as swine fever, porcine reproductive and respiratory syndrome (PRRS), foot-and-mouth disease, and various avian influenza strains. Utilizing advanced biotechnology and large-scale manufacturing processes, the company operates high-standard production facilities compliant with Good Manufacturing Practice (GMP) requirements. Hile Bio-Technology emphasizes innovation through its dedicated research and development centers, aiming to enhance animal disease prevention and control. The company serves large-scale farming enterprises and veterinary service providers, maintaining a significant presence in the animal health sector through its commitment to product quality and technical support.

Recent filings

Filing Released Lang Actions
海利生物关于对上海证券交易所《关于上海海利生物技术股份有限公司2025年半年度报告的信息披露监管问询函》的回复公告
Interim / Quarterly Report Classification · 95% confidence The document is a detailed reply from Shanghai Haili Biological Technology Co., Ltd. to an inquiry letter from the Shanghai Stock Exchange regarding the company's 2025 semi-annual report. It contains extensive financial data, segment performance, explanations of revenue declines, accounts receivable details, and management's responses to regulatory questions. The content focuses on the company's half-year financial performance and operational details, including segment revenues, costs, and profitability for 2024 Q4 and 2025 Q1 and Q2. This aligns with a comprehensive interim or quarterly financial report rather than a brief announcement or a certification. The document is lengthy (15,000 characters) and contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-10-28 Chinese
上海市通力律师事务所关于上海海利生物技术股份有限公司2025年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, and voting results of the 2025 first extraordinary general meeting (临时股东大会) of Shanghai Haili Biotechnology Co., Ltd. It details the legality of the meeting's call, attendance, voting procedures, and results. The document is not a full annual report, audit report, or financial statement. It is not a proxy solicitation or a voting results announcement alone, but a legal opinion on the meeting and its resolutions. The document is lengthy (6874 characters) and contains detailed legal verification and conclusions about the shareholder meeting. This type of document is best classified under Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official voting results and legal opinions on the shareholder meeting proceedings and outcomes.
2025-10-09 Chinese
海利生物2025年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the company's first extraordinary general meeting of shareholders in 2025. It details the meeting date, attendance, voting results on various proposals, and legal witness statements confirming the validity of the meeting and voting process. The content focuses on the official voting results and resolutions passed at the shareholders' meeting. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a presentation or a proxy solicitation but an official announcement of voting results from a shareholders meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail support this classification with high confidence.
2025-10-09 Chinese
海利生物2025年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the "2025 First Extraordinary General Meeting of Shareholders" of Shanghai Haili Biotechnology Co., Ltd. It contains detailed agenda items, voting procedures, and extensive proposed amendments to the company's articles of association and governance rules. The content focuses on governance changes, shareholder meeting procedures, and company bylaws revisions. There is no financial data, earnings information, or audit content. The document is clearly the materials provided for a shareholders' meeting, not the meeting minutes or voting results. Therefore, it fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting.
2025-09-25 Chinese
海利生物第五届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 15th meeting of the 5th Board of Directors of Shanghai Haili Biotechnology Co., Ltd. It details the meeting date, attendance, agenda items, and voting results. It includes information about approval of a price adjustment for a major asset purchase and the scheduling of an extraordinary general meeting. The document is a formal board meeting resolution announcement, not a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a call transcript or regulatory certification. Therefore, it fits best under 'Board/Management Information' (MANG), which covers announcements of changes or decisions by the board of directors.
2025-09-15 Chinese
海利生物关于召开2025年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2025 first extraordinary general meeting of shareholders (临时股东大会) for Shanghai Haili Biotechnology Co., Ltd. It includes information about the meeting date, voting methods, agenda items, and proxy voting instructions. It does not contain financial statements or results but is focused on informing shareholders about the meeting logistics and agenda. The document length is under 5,000 characters and is clearly a meeting notice rather than the meeting materials or results. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-09-15 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.